CSI Market
Sign In | Register

Vor Biopharma Inc (VOR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access VOR Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Vor Biopharma Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-282.39
Depreciation & amortization0.06
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation18.27
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants207.66
Operating Lease Expense0.11
Interest Amortization Accretion On Marketable Securities-
Transaction Costs For Issuance Of Pre- Funded Warrants-
Issuance Of Pre- Funded Warrants In Connection With The Acquisition Of In- Process Research And Development-
Increase Decrease In Operating Lease Liability-0.06
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.30
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets6.08
Other Working Capital0.03
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-13.03
Discontinued operations0.00
Net Cash flow from Operating Activities-63.62
Investing Activities
Capital Expenditures-0.17
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities55.90
Payments to Acquire Marketable Securities-355.50
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-299.77
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock74.77
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Initial Public Offering And Concurrent Private Placement-
Proceeds From Stock Options Exercised And Issuance Of Common Stock Under Espp-
Payment Of Issuance Costs Related To Underwritten Public Offering And Concurrent Private Placement-
Proceeds From Stock Option Exercises And The Issuance Of Shares Under Espp-
Payment Of Issuance Costs Related To Underwritten Public Offering And Private Placements-
Proceeds From Issuance Of Common Stock From Underwritten Public Offering Net Of Underwriting Discount And Commissions-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities74.76
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-63.79
Total Cash Flow-288.63
4 historic quarters locked

Sign in to unlock the full Vor Biopharma Inc cash flow history.

Sign In Create Free Account

About Vor Biopharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 11, 2026
  • Source: vor-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-343607

Figures are derived from filed reports and may be restated. Historical data is subject to revision.